Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors
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SUPPLEMENTARY METHODS
Human mononuclear cells
Human bone marrow samples were obtained from AML patients according to institutional guidelines as previously described [28] . Studies were approved by human ethics committees of the Royal Adelaide Hospital, the University of Newcastle, the South Eastern Sydney and Illawarra Area Health Service, and the Hunter New England Area Health. Mononuclear cells were isolated by Ficoll-Hypaque density-gradient centrifugation, washed, and resuspended at 5 × 10 5 /mL in IMDM, 0.5% FCS, 1% penicillin/streptomycin. In some experiments cells were cultured in the presence of 50 ng/ml FL as indicated. All samples had a minimum of 75% AML blasts. FLT3 status was determined using routine pathology, and was confirmed by genomic DNA sequencing utilizing juxtamembrane domain (Forward-5′-GCAATTTAGGTATGAAAGCCAGC-3′, Reverse-5′-CTTTCAGCATTTTGACGGCAACC-3′) and kinase domain (Forward-5′-TTCACAGAGACCTGGCCG-3′, Reverse-5′-GCCCAAGGACAGATGTGATG-3′) specific primers and sequenced by Sanger sequencing (AGRF; Brisbane, Australia). FACS purification of primary human CD34 +
CD38
-CD123 + leukemic stem and progenitor cells (LSPCs) was performed as previously described [28] .
For primary human CD34 + bone marrow cells, 500 cells were seeded in duplicate into 6-well culture plates with 1.1 ml methocult (StemCell Technologies, #H4034) in 0, 1 or 3 µM FTY720 or AAL(S). Total colonies were counted after 7 days and differential colonies counted after 14 days according to manufacturer's instructions.
Antibodies used for immunoblotting
The following primary antibodies were used for immunoblotting: anti-PP2A-A (Calbiochem); anti-PP2A-B56α, anti-PP2A-B56γ3, anti-PP2A-B56δ, and anti-PP2A-B56ε (Novus Biochemicals); anti-PP2Ac
, anti-pSTAT5 Y694 , anti-pJAK2 Y221 , anti-AKT, anti-ERK1/2, anti-MEK, anti-p38MAPK and anti-STAT5 (Cell Signaling Technology, Inc.); and anti-β-actin (ACTB) (Sigma Aldrich). Affinity-purified rabbit antibodies against PP2A-B55α 30 and PP2A-C 31 were previously described. Pixel densitometry volume quantification was determined using Multi Gauge software.
Statistical analysis
Statistical significance of differences between samples was assessed using a Student's t-test. Values shown are the mean ± SEM. All analyses were performed using GraphPad Prism 5 software (GraphPad Software Inc, CA, USA). IC 50 values were calculated using cubic spline regression analysis using GraphPad Prism 5.0. For co-culture combination assays, synergy was determined by the Fractional Product method, calculated according to Webb 4 cells/well, and growth determined by resazurin reduction over time. (E) PP2A complexes were isolated from FDC.P1 mouse myeloid cells transduced with WT FLT3, and grown in the presence of granulocytemacrophage-colony stimulating factor (GM) or FLT3 ligand (FL), treated with or without 3 µM FTY720 or AAL(S) for 12 h, using immunoprecipitation with an anti-PP2A-C antibody. PP2A activity was determined by incubating the isolated PP2A-C complex with a PP2A-specific phosphopeptide and measuring free phosphate release using a colorimetric assay. Activity was calculated as a percentage of control WT-GM cells Columns; mean, bars; SEM, *p < 0.05, compared to WT-GM or untreated cells, as indicated; Students t test. (B) Gene expression data from U133+2.0 microarrays was normalised in R using the JustRMA() function in the affy library. For both datasets, the mean expression level of each PP2A subunit gene in FLT3 mutation positive samples was compared to non-mutated normal karyotype samples using a two-tailed t-test with p < 0.05. Box and whiskers plots show the median, first quartile and third quartile (box) and upper and lower limits of expression (whiskers) for each gene in FLT3 mutation negative and positive samples.
were treated with FTY720, AG1296 or CEP701 for 48 hr. Survival is the percentage of annexin V negative cells. (D-E) Normal bone marrow CD34+ cells (n = 4-6) were obtained from StemCell Technologies. Cells were seeded in duplicate full cytokine complement methylcellulose and treated with FTY720 or AAL(S) at the indicated concentrations. (D) After 7 days total colony number was counted. (E) After 14 days differential colonies were scored and categorized as colony forming unit erythroid (CFU-E), burst forming unit erythroid (BFU-E), or colony forming unit granulocyte, macrophage (CFU-GM). (F-G) Normal human bone marrow CD34+ cells were purchased from Lonza (n = 2) and seeded in duplicate in full cytokine complement methylcellulose and treated with FTY720 or AAL(S) at the indicated concentrations. (F) After 7 days total colony number was counted. (G) After 14 days differential colonies were scored.Columns; mean, bars; SEM. There were no significant differences with any drug treatments compared to control untreated cells. 
